We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Octopus Group

DRG International, Inc.

DRG International, a global innovator of high-quality medical diagnostics and equipment, provides the medical and res... read more Featured Products: More products

Download Mobile App





DRG Instruments Demonstrates DRG:HYBRID-XL Fully Automated Lab Analyzer

By LabMedica International staff writers
Posted on 21 Nov 2019
Print article
Image: DRG:HYBRiD-XL (Photo courtesy of DRG Instruments GmbH)
Image: DRG:HYBRiD-XL (Photo courtesy of DRG Instruments GmbH)
DRG Instruments GmbH (Marburg, Germany) demonstrated its fully automated random access analyzer, DRG:HYBRiD-XL, along with its newest ELISAs, at this year's MEDICA, the world's largest annual medical technology trade fair, that took place from 18-21 November in Düsseldorf, Germany. MEDICA provides the medical device industry with a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The combination of product shows with international congresses, forums, as well as expert workshops, and the exchange of professional views make MEDICA a meeting point for international professionals from various fields in the medical sector.

DRG Instruments specializes in the development and production of innovative ELISAs and Chemiluminescent assays, both for routine and research applications, in the fields of diabetes diagnosis, endocrinology, prenatal/neonatal supervision, thyroid function and many more. Recently, DRG Instruments developed the world’s first nonradioactive immunoassays for the determination of active Renin and PLGF, as well as a complete panel of sensitive assays for the quantitative determination of saliva steroids. In the last five years, DRG Instruments has developed its own tumor marker panel and a broad range of ELISAS in the field of infectious diseases, including the world’s first assay for the qualitative detection of human Fasciola IgG.

At the MEDICA 2019 International Trade Fair, DRG demonstrated DRG:HYBRiD-XL, its fully automated, continuous access analyzer that allows the simultaneous measurement of immunoassays and clinical chemistry parameters, including turbidimetric tests, in one sample. It allows medical practitioners to carry out up to 40 tests of different types or 40 times of the same test, or up to 20-patient samples over a wide range of pre-packaged tests to serve different specialties.

Additionally, DRG presented several new DRG ELISAs, including Bordetella pertussis Toxin IgA/IgG (quantitative), Aspergillus fumigatus IgG/IgM and Bartonella Ab, at the event. The company also displayed its new and optimized SALIVA ELISAs: Unique Salivary Hepcidin and optimized Salivary Estradiol. The company’s saliva diagnostics products offer several benefits such as non-invasive sampling, measurement of the free (unbounded) fraction of steroids, and much higher diagnostic relevance with reproducible and reliable results, compared to serum analytics.

Related Links:
DRG Instruments GmbH

Gold Supplier
Anti-SARS-CoV-2 Controls Kit
ACCURUN Anti-SARS-CoV-2 Controls Kit
New
Automatic Blood Coagulation Analyzer
BCA-3000
New
Lab Incubator
IN-010
New
Celiac Disease PCR Test
XeliGen XL

Print article

Channels

Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more

Immunology

view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more

Microbiology

view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more

Pathology

view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more

Technology

view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more

Industry

view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.